This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
Malignant Neoplasm of Ovary, C56난소의 악성신생물 (난소암)
Special Copayment Reduction V193 — copayment 5% of covered medical care costs applied for 5 years from the date of cancer patient registration (Cancer Control Act and National Health Insurance special copayment reduction regulations) Adult onset: very high | ICD-10: C56
Ovarian cancer is the gynecologic malignancy with the highest mortality, and the history of its clinical recognition developed relatively late. The first systematic description of ovarian neoplasms dates back to the early 1800s epoch. In 1809, Ephraim McDowell of Kentucky, USA, successfully performed surgery to remove an ovarian cyst, which is recorded as the beginning of intra-abdominal surgery. In 1809 this operation was performed without anesthesia, but the patient survived, proving for the first time the feasibility of abdominal surgery.
In the late 19th to early 20th centuries, ovarian malignancies began to be resected surgically, but treatment outcomes were extremely poor. In 1958, the first cooperative clinical trial group, the predecessor of the US GOG (Gynecologic Oncology Group), was formed, and systematic clinical research on gynecologic malignancies began. In 1976, the GOG evaluated the efficacy of alkylating agent-based chemotherapy (chlorambucil, cyclophosphamide) in treating ovarian cancer.
In the 1970s, when the anticancer effect of cisplatin was confirmed, a revolutionary change occurred in the treatment of ovarian cancer. In 1989, paclitaxel (Taxol) was reported to be highly effective in ovarian cancer, and in 1996 the GOG-111 and OV10 clinical trials established carboplatin + paclitaxel combination therapy as the standard first-line chemotherapy.
In 2003, as the association of BRCA1 (discovered 1994, Myriad Genetics) and BRCA2 (discovered 1995) with ovarian cancer risk was systematically analyzed, the concept of hereditary ovarian cancer was established. The lifetime risk of ovarian cancer in women with BRCA1/2 mutations is reported to be 40–60% and 15–30%, respectively.
In 2014–2015, olaparib (a PARP inhibitor) received FDA and EMA approval for BRCA1/2-mutant recurrent ovarian cancer, opening a new era of targeted therapy. Subsequently, the indications for niraparib (2017), rucaparib (2016), and olaparib/niraparib maintenance therapy were expanded, and combined maintenance therapy with bevacizumab + olaparib (PAOLA-1) was also established. In 2022, the era of precision oncology with treatment selection based on BRCA/HRD began in earnest in ovarian cancer. In March 2024, mirvetuximab soravtansine (Elahere) received full FDA approval for folate receptor α (FRα)-positive platinum-resistant ovarian cancer, opening a new chapter in ADC (antibody-drug conjugate) therapy.
2. Causes
The causes of ovarian cancer vary by histologic type. Epithelial ovarian carcinoma (EOC) accounts for about 90% of all ovarian cancers and is the most studied type.
Genetic causes
BRCA1/BRCA2 germline mutations: about 15–20% of all epithelial ovarian cancers are related to BRCA1/2 mutations. The lifetime risk of ovarian cancer is 40–60% for women with BRCA1 mutations and 15–30% for those with BRCA2 mutations. They are strongly associated mainly with the high-grade serous ovarian cancer (HGSOC) histologic type.
Lynch syndrome: germline mutations of MLH1, MSH2, MSH6, PMS2. The risk of endometrial cancer is higher, but the risk of ovarian cancer (mainly endometrioid and clear cell types) is also increased by 2–14%.
Other HRR genes: germline mutations of RAD51C, RAD51D, BRIP1, PALB2 and others also increase the risk of ovarian cancer about 2–6 times.
Reproductive and endocrine risk factors
Number of ovulations: 'incessant ovulation theory': repeated damage and repair of the ovarian surface epithelium with repeated ovulation raises the risk of malignant transformation.
Nulliparity: increased risk in women who have never given birth. Conversely, oral contraceptive use and breastfeeding have a protective effect.
Infertility treatment (assisted reproduction): association suggested in some studies; debate continues
Postmenopausal hormone therapy (estrogen alone): there are reports that estrogen-alone therapy slightly increases the risk of serous ovarian cancer.
Obesity: positive correlation between BMI and ovarian cancer risk
Environmental factors
Asbestos exposure: possible overlapping risk with peritoneal mesothelioma
Talc use: an association between perineal talc application and ovarian cancer risk has been suggested, but there is no conclusive evidence
3. Genetics
The genomic features of ovarian cancer differ distinctly by histologic type, and TCGA's analysis of high-grade serous ovarian cancer (2011) provides the most comprehensive data.
Genomic features of high-grade serous ovarian cancer (HGSOC)
TP53 mutation: somatic TP53 mutations in more than 96% of HGSOC. It is the most universal genetic abnormality of HGSOC and occurs at an early stage of pathogenesis.
BRCA1/2 mutation: germline BRCA1/2 mutations about 15–20%, somatic BRCA1/2 mutations about 5–7%, BRCA1 promoter methylation about 11–12%: in total, homologous recombination deficiency (HRD) is observed in about 50%.
NF1 deletion: deletion or inactivation in about 24%
RB1 deletion: about 22%
CDK12 mutation: about 3–4%. Loss of CDK12 function increases dependence on the NHEJ pathway → vulnerability to apoptosis
MYC amplification: 8q24 amplification in about 24%
CCNE1 (cyclin E1) amplification: 19q12 amplification in about 20%. Associated with PARP inhibitor resistance
Low-grade serous ovarian cancer (LGSOC) and other histologic types
LGSOC: TP53 mutations are rare; characterized by KRAS/BRAF/NRAS/MAP2K1 mutations (MAPK pathway activation). Clinical trials of MEK inhibitors (binimetinib) are under way.
Clear cell carcinoma (CCC): ARID1A mutations (about 46–57%), PIK3CA mutations (about 40–50%). HNF1β overexpression. MSI-H is higher than in other types (about 10–20%). A relatively high proportion is observed in Korea and Japan (about 10–14% of all ovarian cancers).
Endometrioid: CTNNB1 (β-catenin) mutations, PTEN deletion, MMR deficiency. Strong association with endometriosis.
HRD (homologous recombination deficiency) status is a key biomarker for predicting sensitivity to PARP inhibitors and platinum chemotherapy. Commercial HRD tests such as the Myriad myChoice HRD test and FoundationOne are used clinically. In Korea, BRCA1/2 germline testing and tumor tissue HRD score testing are covered by National Health Insurance.
4. General epidemiology
Ovarian cancer is the gynecologic malignancy with the highest mortality; worldwide, about 313,000 women are diagnosed and about 207,000 die each year (2020). In Korea too, incidence is gradually increasing, and mortality has not declined.
Global situation
Incidence is high in developed countries (North America and Western Europe ASR about 10–12/100,000) and relatively low but increasing in East Asia. More than about 40% are diagnosed with distant metastasis (stage IV), so the 5-year survival rate is low.
Situation in Korea
In Korea, as of 2020, the age-standardized incidence of ovarian cancer is estimated at about 8–9 per 100,000 women. The 5-year relative survival rate is about 44.4–63.8%, the lowest among the major gynecologic cancers. Together with pancreatic cancer, it shows a trend of increasing mortality. The median age at diagnosis is about 55–60 years, and it is not uncommon in the 30s–40s. Clear cell carcinoma (CCC) shows a relatively higher proportion in East Asian women, such as in Korea and Japan, than in Western women (about 10–14%).
Category
Figure
Notes
New diagnoses worldwide (2020)
About 313,000
8th most common cancer in women
Korean 5-year survival rate
44.4% (distant metastasis) / 63.8% (overall)
Based on KCCR
Proportion of clear cell carcinoma in Korea
~10~14%
Higher than in Western countries (5–6%)
Proportion with BRCA1/2 mutations
~15~20%
Germline, HGSOC
Proportion at stage III–IV at diagnosis
>40%
Nonspecific symptoms, late detection
First-line PARP inhibitor maintenance PFS in Korea (2023)
Median 45.3 months
BRCA mut, olaparib/niraparib cohort of 96 patients
5. Pathophysiology
Pathophysiology of high-grade serous ovarian cancer (HGSOC)
Understanding of the origin of HGSOC has changed greatly over the past 10–15 years. Traditionally it was understood to originate from the ovarian surface epithelium (OSE) or ovarian cortical inclusion cysts, but the 'tubal origin hypothesis' now predominates: HGSOC arises from cells of the fallopian tube epithelium showing the p53 signature, particularly at the fimbriated end of the tube. A TP53 mutation occurs as an early event in the secretory cells of the fallopian tube, and as HRD due to loss of BRCA1/2 function is superimposed, genomic instability increases sharply, progressing from STIC (serous tubal intraepithelial carcinoma) → invasive HGSOC. The finding of STIC in the fimbriae of fallopian tubes removed during BRCA1/2 prophylactic surgery (risk-reducing salpingo-oophorectomy, RRSO) is strong evidence for the tubal origin hypothesis.
Pathophysiology of low-grade serous ovarian cancer (LGSOC)
A model of sequential progression from serous borderline tumor (SBT) → LGSOC is supported. MAPK pathway mutations such as KRAS, BRAF, NRAS and MAP2K1 are observed at an early stage, suggesting a pathogenesis completely different from HGSOC. LGSOC is resistant to chemotherapy but sensitive to MEK inhibitors.
Pathophysiology of clear cell carcinoma (CCC)
Endometriosis is strongly supported as a precursor lesion of CCC and endometrioid ovarian cancer. Oxidative stress due to excessive iron accumulation in endometriomas and ARID1A mutation (loss of BAF250a) impair the function of the SWI/SNF complex, causing failure of chromatin opening and gene expression regulation. Superimposed activation of the PI3K/AKT/mTOR pathway by PIK3CA mutation leads to progression to invasive CCC.
HRD and PARP inhibitor sensitivity
Cells with a damaged homologous recombination repair (HRR) pathway (HRD) cannot repair the single-strand DNA breaks induced by PARP inhibitors, so double-strand breaks accumulate and the cells undergo apoptosis. This is called synthetic lethality.
6. Symptoms
Ovarian cancer has been called the 'silent killer' because its early symptoms are extremely nonspecific. In reality, however, symptoms are present in about 70–75% of patients; the problem is that these symptoms are hard to distinguish from common gastrointestinal and urinary symptoms.
Main symptoms
Abdominal bloating: the most common symptom. Abdominal distension due to ascites formation or the tumor itself
Pelvic/abdominal pain: persistent or intermittent dull pain. Sudden severe pain occurs with torsion of an ovarian tumor.
Early satiety and anorexia: compression of the stomach and bowel causes a feeling of fullness even after a small meal.
Urinary symptoms: frequency and urgency due to bladder compression
Bowel symptoms: constipation, diarrhea and changes in bowel habits due to bowel compression or invasion
Weight change: weight gain due to ascites formation or weight loss due to cancer cachexia
Fatigue and reduced activity
Abnormal vaginal bleeding: with hormone-secreting ovarian tumors (granulosa cell tumor, theca-lutein cell tumor) or accompanying peritoneal endometriosis
Acute abdomen: with torsion of an ovarian tumor or rupture of an ovarian cyst
Abdominal bloating, pelvic pain, anorexia and urinary frequency that occur 12 or more times per month and are new or worsening within 1 year are high-risk symptoms of ovarian cancer requiring immediate medical evaluation.
7. Signs
Physical examination findings
Pelvic mass: on bimanual examination, an ovarian mass or an irregular, fixed pelvic mass is palpated. A nodular surface and hard consistency strongly suggest malignancy.
Ascites: findings of abdominal distension + shifting dullness + fluid wave. This is a characteristic finding of peritoneal metastasis of ovarian cancer.
Omental cake: a hard, irregular plate-like mass palpated in the upper abdomen suggests omental metastasis (omental cake).
Sister Mary Joseph nodule: a metastatic nodule around the umbilicus. A sign of advanced peritoneal metastasis.
Pleural effusion: right-predominant pleural effusion, dyspnea due to perforation
Lymphadenopathy: inguinal and supraclavicular lymphadenopathy
Rectovaginal septum mass: a hard, nodular mass felt on digital rectal examination suggests metastasis to the pouch of Douglas (cul-de-sac).
Signs of hormone hypersecretion (functioning ovarian tumors)
To date, ovarian cancer screening of the general population is not recommended. Large clinical trials (UKCTOCS, PLCO) confirmed that combined CA-125 + transvaginal ultrasound screening did not significantly reduce ovarian cancer mortality.
Surveillance of high-risk groups
BRCA1/2 mutation carriers: annual transvaginal ultrasound + CA-125 testing is performed, but the utility of screening is limited. Risk-reducing salpingo-oophorectomy (RRSO) is the most effective preventive strategy.
Women with Lynch syndrome: consider regular gynecologic examinations and transvaginal ultrasound.
Carriers of other HRR gene mutations (RAD51C/D, BRIP1, etc.): genetic counseling and an individualized surveillance plan with a specialist
Limitations of screening biomarkers
CA-125 is positive in only about 50–60% of early ovarian cancers (stage I) and is also elevated in benign conditions such as endometriosis, pelvic inflammatory disease, menstruation and pregnancy. HE4 (Human Epididymis Protein 4) has higher specificity than CA-125 and is used together with it to calculate the ROMA (Risk of Ovarian Malignancy Algorithm) index.
9. Diagnosis
Blood tests
CA-125: diagnostic aid for HGSOC and monitoring of treatment response. Upper limit of normal 35 U/mL
HE4: used with CA-125 to calculate the ROMA index. Premenopausal ROMA ≥ 11.4% and postmenopausal ROMA ≥ 29.9% are classified as high risk
AFP (α-fetoprotein): diagnostic aid for germ cell tumors (endodermal sinus tumor)
β-hCG: choriocarcinoma, germ cell tumors
LDH: germ cell tumors (dysgerminoma)
Inhibin (Inhibin A/B): monitoring of granulosa cell tumor
Imaging
Transvaginal ultrasound (TVS): initial evaluation. Assesses the size of the ovarian mass, internal echo pattern (solid components, septa, papillary projections) and presence of ascites. The IOTA classification (Simple Rules, ADNEX model) is useful for predicting malignancy
CT (abdomen/pelvis/chest): evaluates the extent of peritoneal metastasis, lymph node status and distant metastasis. Essential for preoperative assessment of resectability
MRI (pelvis): evaluates the tissue characteristics of ovarian masses (cystic vs. solid, fat, hemorrhage, fibrosis, etc.). Evaluates rectal or bladder invasion
PET-CT: detection of recurrence and evaluation of treatment response
FIGO 2014 staging
Stage
Definition
IA
Confined to one ovary, capsule intact, no surface tumor, negative washings
IB
Confined to both ovaries, capsule intact, no surface tumor, negative washings
IC
IA/IB with any of capsule rupture, surface tumor, or positive washings/ascites
IIA/IIB
Pelvic extension (uterus, fallopian tubes, other pelvic structures)
IIIA~IIIC
Peritoneal metastasis (outside the pelvis); lymph node metastasis
IVA/IVB
Pleural effusion (cytology positive)/distant organ metastasis
Final histological diagnosis
Intraoperative frozen section examination confirms malignancy and determines the extent of surgery. Final pathology confirms histologic type (HGSOC, LGSOC, CCC, endometrioid, mucinous, other), grade, depth of invasion, lymph node status and peritoneal metastasis. Immunohistochemistry: WT1, p53 (overexpression/complete loss pattern), PAX8 and ER/PR are used in diagnosing HGSOC.
10. Treatment
Surgical treatment
The surgical principle for epithelial ovarian cancer is 'maximal tumor debulking (debulking surgery).' R0 (complete resection) or minimization of residual tumor (<1 cm) is the most important surgical goal determining prognosis.
Early stage (I–II): total hysterectomy + bilateral salpingo-oophorectomy + pelvic and para-aortic lymphadenectomy + omentectomy + peritoneal biopsies (comprehensive surgical staging)
Advanced stage (III–IV): primary debulking surgery (PDS) or interval debulking surgery (IDS) after neoadjuvant chemotherapy
Extent of surgery: extensive organ resection such as pelvic peritoneal stripping, colectomy, small bowel resection, splenectomy and diaphragmatic resection may be needed
Chemotherapy
Standard first-line regimen: carboplatin (AUC 5–6) + paclitaxel (175 mg/m²) every 3 weeks for 6 cycles. Intraperitoneal administration (IP chemotherapy, GOG-172): survival benefit in patients with peritoneal metastasis (OS 65.6 months vs. 49.7 months), but adherence problems due to toxicity
Neoadjuvant chemotherapy (NACT): IDS after 3–4 cycles of carboplatin + paclitaxel. The CHORUS and EORTC 55971 studies confirmed survival equivalent to PDS. May lower surgical morbidity in patients with bulky tumors
Addition of bevacizumab: PFS benefit in the GOG-0218 (United States) and ICON7 (Europe) studies. Survival benefit in high-risk patients (stage III with residual tumor >1 cm, stage IV). Combined during standard chemotherapy and as maintenance therapy
PARP inhibitor maintenance therapy
Olaparib (Lynparza): first-line maintenance therapy for BRCA1/2 mutation-positive HGSOC (SOLO-1: mPFS 56.0 months vs. 13.8 months). Efficacy extended to HRD-positive disease (PAOLA-1: combined bevacizumab+olaparib maintenance)
Niraparib (Zejula): first-line maintenance therapy (PRIMA study). Can be used in all patients regardless of BRCA mutation status. Individualized dosing strategy (100 mg or 200 mg according to adjusted body weight and platelet count)
Korean real-world data: Korean Asan Medical Center cohort (2015–2023, n=70, first-line maintenance): 2-year PFS 75.5%, 3-year OS 98.5%. Cohort of 96 patients from 9 Korean institutions (2014–2022): median PFS 45.3 months
PAOLA-1: bevacizumab + olaparib combined maintenance vs. bevacizumab maintenance alone — median PFS 22.1 vs. 16.6 months in BRCA mut/HRD-positive (overall), 37.2 vs. 21.7 months in BRCA mut
Mirvetuximab soravtansine (Elahere): full FDA approval (March 2024) for FRα-positive (IHC 2+ or higher) platinum-resistant ovarian cancer. MIRASOL trial: mOS 16.5 months vs. 12.7 months (vs. chemotherapy). SORAYA trial (single-arm study): ORR 32.4%
Bevacizumab: PFS benefit when combined with PLD/gemcitabine/weekly paclitaxel in platinum-resistant recurrence in the AURELIA study
11. Prognosis
5-year survival rate by stage
FIGO stage
5-year survival (US/worldwide)
Korea
Stage I
80~93%
Diagnosis at stage I is rare, but prognosis is favorable
Stage II
60~70%
—
Stage III
25~45%
—
Stage IV
10~20%
44.4% (all distant metastasis)
Overall (Korea)
~63.8%(2010~2014)
Based on KCCR
Prognostic factors
FIGO stage: the most important prognostic factor
Residual tumor size: R0 (complete resection) has the greatest effect on survival. The OS difference between no residual tumor and >1 cm ranges from months to years
BRCA1/2 mutation: BRCA mut positivity is, on the contrary, associated with higher sensitivity to platinum and PARP inhibitors and a relatively better prognosis
Histologic type: HGSOC 5-year survival about 30–40% at stage 3; clear cell carcinoma has a favorable prognosis at stage I (about 70–85%) but very poor at advanced stages (5-year OS <15%)
Postoperative residual tumor: whether complete resection (no visible residual) is achieved
Chemotherapy response: platinum sensitivity
Rate of CA-125 response: rapid normalization of CA-125 during treatment
12. Prevention
Oral contraceptives
Use of combined oral contraceptives (COC) is the most powerful chemopreventive measure, reducing the risk of ovarian cancer by 40–50%. The protective effect increases in proportion to the duration of use (50% reduction with 5 years of use) and persists for up to 15–20 years after stopping. The ovarian cancer preventive effect of COC has also been confirmed in BRCA1/2 mutation carriers, but it must be balanced against a possible slight increase in breast cancer risk.
Risk-reducing salpingo-oophorectomy (RRSO)
In BRCA1/2 mutation carriers, RRSO (risk-reducing salpingo-oophorectomy) is the most effective preventive method, reducing the risk of ovarian cancer by about 80–96%. Recommended timing: age 35–40 or after completion of childbearing for BRCA1 mutations, and age 40–45 for BRCA2 mutations. Performing only risk-reducing salpingectomy (RRLS) before RRSO is also being studied at some institutions. In Korea, prophylactic surgery for women with confirmed BRCA1/2 mutations is covered by National Health Insurance.
Childbirth and breastfeeding
Childbirth (multiparity) and breastfeeding lower the risk of ovarian cancer. A first delivery reduces risk by about 40–50%, with each additional delivery reducing it by a further 10–15%. Breastfeeding reduces risk in proportion to its duration.
Genetic counseling and genetic testing
In high-risk women with a family history (ovarian or breast cancer in first- or second-degree relatives), genetic counseling and panel testing for BRCA1/2 and other HRR genes are performed. In Korea, high-risk women can be tested through the state-supported genetic testing coverage system. When a mutation is confirmed, prophylactic surgery or an enhanced surveillance program is individualized.
Treatment of endometriosis
Given the confirmed association between endometriosis and clear cell and endometrioid ovarian cancer, active treatment and follow-up of endometriosis may have an indirect preventive effect.
13. References
Sung H, et al. Global Cancer Statistics 2020. CA Cancer J Clin. 2021;71(3):209-249.
TCGA Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011;474(7353):609-615.
Clinical Outcomes of PARP Inhibitors as Maintenance Therapy in Korean Ovarian Cancer. PMC11593207. 2024.
Real-world efficacy of olaparib in Korean ovarian cancer patients with exploratory BRCA analysis. PubMed 39923681. 2025.
Comparison of olaparib and niraparib in BRCA-mutated, newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2024.
Ray-Coquard I, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer (PAOLA-1). N Engl J Med. 2019;381(25):2416-2428.
Mirvetuximab Soravtansine FDA Full Approval (ELAHERE). FDA. March 22, 2024. NCI Cancer Currents Blog.
Moore KN, et al. Mirvetuximab Soravtansine in FRα-positive platinum-resistant ovarian cancer (MIRASOL). N Engl J Med. 2023;389(23):2162-2174.
Cancer Statistics in Korea 2023. PMC13093029. 2026.
Korean Society of Gynecologic Oncology. Clinical Practice Guidelines for Ovarian Cancer: 2025 Update. J Gynecol Oncol. 2025;36:e69.
Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights. ESMO Open. 2024.
Incidence and survival of gynecologic cancer in Korea 1999-2019: KCCR. PMC10663396. 2023.